Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Hepatocellular 9Neoplasms 4Melanoma 4Breast Neoplasms 4Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Sarcoma 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycystic Ovary Syndrome 2Pleural Effusion, Malignant 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Anxiety Disorders 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Recurrence 1Rare Malignant Neoplasm 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphedema 1Locally Advanced Bladder Cancer 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Everolimus 5Cetuximab 2volagidemab 1tanezumab 1pembrolizumab 1inavolisib 1Vemurafenib 1Trimetazidine 1Sirolimus 1Secretin 1SF 1126 1Pharmaceutical Preparations 1Panobinostat 1Oxaliplatin 1Nivolumab 1NVP-BKM120 1Leucovorin 1Irinotecan 1Fulvestrant 1Fluorouracil 1Drug Therapy 1Capecitabine 1CB-839 1CA-19-9 Antigen 1Bevacizumab 1Aspirin 1Alpelisib 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hereditary Sensory and Autonomic Neuropathies × Pharmaceutical Preparations × Clear all
NCT06599619 2026-01-26

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

University of Pittsburgh

Recruiting
30 enrolled
Dermatologic

Dysplastic Nevus Syndrome, Melanoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡